GNTbm-TKI / GNT Biotech - LARVOL DELTA

Preclinical development of GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor, while combined with GNTbm-38 showing potent induced tumor microenvironment remodeling activity in cancer immunotherapy (ESMO 2025) - "Conclusions Collectively, GNTbm-TKI is an anti-cancer drug with potential for cancer immunotherapy, while combined with GNTbm-38, will obtain superior anti-cancer immune benefits, and can also greatly improve the therapeutic benefits through combination with immune checkpoint inhibitors. Legal entity responsible for the study The authors."

IO biomarker • Preclinical • Tumor microenvironment • Colon Cancer • Colorectal Cancer • Head and Neck Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • AXL • CD8 • KDR • NTRK2 • ROS1

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting (PRNewswire) - "The results of the study show that GNTbm-TKI strongly inhibited the activities of TYRO3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 at nanomolar level. GNTbm-TKI showed anti-proliferation activity in NCI-60 human cancer cell lines with low GI50 values. GNTbm-TKI showed a superior in vivo efficacy in WT mice compared to immune-deficient mice in CT-26 model, indicating anti-cancer immune activation induced by the treatment."

Preclinical • Solid Tumor